Dogwood Therapeutics Announces Completion Of 239-Patient Enrollment In Phase 2b Halneuron Trial For Chemotherapy Induced Neuropathic Pain; Topline Data Expected November 2026
Share
Why It Matters
Dogwood finished signing up all 239 patients for their pain medicine test. Now they wait until November 2026 to see if the medicine actually works.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.